The estimated Net Worth of Bruce N. Jacobs is at least $7.75 Миллион dollars as of 27 June 2024. Mr Jacobs owns over 25,000 units of Kymera Therapeutics stock worth over $7,546,163 and over the last 4 years he sold KYMR stock worth over $207,147.
Mr has made over 17 trades of the Kymera Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 25,000 units of KYMR stock worth $52,000 on 27 June 2024.
The largest trade he's ever made was exercising 25,000 units of Kymera Therapeutics stock on 27 June 2024 worth over $52,000. On average, Mr trades about 9,615 units every 61 days since 2020. As of 27 June 2024 he still owns at least 168,554 units of Kymera Therapeutics stock.
You can see the complete history of Mr Jacobs stock trades at the bottom of the page.
Bruce N. Jacobs CFA is the Chief Financial Officer at Kymera Therapeutics.
Bruce's mailing address filed with the SEC is C/O KYMERA THERAPEUTICS, INC., 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472.
Over the last 4 years, insiders at Kymera Therapeutics have traded over $179,227,903 worth of Kymera Therapeutics stock and bought 2,497,406 units worth $70,844,455 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Bros. Advisors Lp667, L.P.B... и Group, Llc Green Jeremy Red.... On average, Kymera Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,989,455. The most recent stock trade was executed by Jeffrey W. Albers on 26 August 2024, trading 5,000 units of KYMR stock currently worth $51,700.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics executives and other stock owners filed with the SEC include: